ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$143M
(+64%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
36
Reduced
44
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORTX
276
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| – | – |
-63,622
| Closed | -$1.05M |
|
|
MRTX
277
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-108,000
| Closed | -$6.35M |
|
278
Dianthus Therapeutics
DNTH
$794M
| – | – |
-481
| Closed | -$5K |
|
279
EyePoint Pharmaceuticals
EYPT
$819M
| – | – |
0
| – | – |
|
|
CBIO
280
Crescent Biopharma, Inc. Common Stock
CBIO
$190M
| – | – |
0
| – | – |
|
281
iShares US Treasury Bond ETF
GOVT
$27.9B
| – | – |
-20,000
| Closed | -$461K |
|
282
Insmed
INSM
$30.1B
| – | – |
0
| – | – |
|